Price Action to Note: Does Tenax Therapeutics Inc Have Any Gas After Today’s Big Increase?

Price Action to Note: Does Tenax Therapeutics Inc Have Any Gas After Today's Big Increase?

The stock of Tenax Therapeutics Inc (NASDAQ:TENX) is a huge mover today! About 78,384 shares traded hands. Tenax Therapeutics Inc (NASDAQ:TENX) has declined 0.94% since March 3, 2016 and is downtrending. It has underperformed by 9.28% the S&P500.
The move comes after 6 months positive chart setup for the $53.37M company. It was reported on Oct, 6 by Barchart.com. We have $4.84 PT which if reached, will make NASDAQ:TENX worth $66.71 million more.

Analysts await Tenax Therapeutics Inc (NASDAQ:TENX) to report earnings on January, 2. After $-0.17 actual earnings per share reported by Tenax Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

According to Zacks Investment Research, “Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation and implanted glucose sensing. Tenax Therapeutics Inc., formerly known as Oxygen Biotherapeutics, Inc., is based in United States.”

More notable recent Tenax Therapeutics Inc (NASDAQ:TENX) news were published by: Businesswire.com which released: “Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan” on October 05, 2016, also Businesswire.com with their article: “Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)” published on September 16, 2014, Businesswire.com published: “Tenax Therapeutics Announces Second Quarter 2016 Financial Results and …” on August 11, 2016. More interesting news about Tenax Therapeutics Inc (NASDAQ:TENX) were released by: Businesswire.com and their article: “Tenax Therapeutics Highlights Completion of Enrollment for LeoPARDS Trial by …” published on December 22, 2015 as well as Businesswire.com‘s news article titled: “Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS” with publication date: February 01, 2016.

TENX Company Profile

Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc., incorporated on April 17, 2008, is a specialty pharmaceutical firm focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity. The Company’s lead product is levosimendan, a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Firm is also developing Oxycyte, a systemic perfluorocarbon, or PFC, product, which is oxygen carrier for use in situations of acute ischemia. In addition, it also has developed a family of perfluorocarbon oxygen carriers for use in personal care, topical wound healing, and other topical indications. Life Newco, Inc. is the wholly owned subsidiary of the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment